Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype

Trial Details

NCT ID
NCT06947967
Phase
PHASE3
Sponsor
Chipscreen Biosciences, Ltd.
Status
RECRUITING
Cancer Type
Follicular Lymphoma Lymphoma
Interventions
  • CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
  • Tucidinostat
  • Placebo
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Provide written informed consent for the study.
  • Male or female, age ≥ 18 years and ≤80 years.
  • ECOG PS 0,1 or 2.
  • Participants with histologically proven peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH), including: a. angioimmunoblastic …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Follicular Lymphoma Lymphoma Trials on Trialify →